Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment

Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00287-20. doi: 10.1128/AAC.00287-20. Print 2020 Jun 23.

Hannah Yejin Kim^{1

2

3}, Shashikant Srivastava⁴, Hemanth Kumar Ak⁵, Ben J Marais^{3

6}, Jan-Willem Alffenaar^{7

2

3}

¹ Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia hannah.kim@sydney.edu.au.
² Westmead Hospital, Westmead, Australia.
³ Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Camperdown, Australia.
⁴ Texas Tech University Health Science Center, School of Pharmacy, Division of Clinical and Translational Research, Dallas, Texas, USA.
⁵ National Institute for Research in Tuberculosis, Chennai, India.
⁶ Department of Infectious Diseases and Microbiology, The Children's Hospital at Westmead, Westmead, Australia.
⁷ Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, Australia.

No abstract available

Keywords: PK/PD; TDM; drug exposure; linezolid; pharmacokinetics; precision dosing; tuberculosis.

Publication types